Spots Global Cancer Trial Database for capivasertib

Every month we try and update this database with for capivasertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer	NCT03742102	Triple Negative...	Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der...	18 Years - 130 Years	AstraZeneca
Capivasertib China PK Study	NCT04742036	Advanced Solid ...	Capivasertib Paclitaxel	18 Years - 130 Years	AstraZeneca
Capivasertib China PK Study	NCT04742036	Advanced Solid ...	Capivasertib Paclitaxel	18 Years - 130 Years	AstraZeneca
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)	NCT04439123	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Capivasertib	18 Years -	National Cancer Institute (NCI)
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer	NCT03801369	Anatomic Stage ... Metastatic Trip...	Biopsy Capivasertib Ceralasertib Durvalumab Olaparib Quality-of-Life... Selumetinib	18 Years -	OHSU Knight Cancer Institute
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours	NCT04958226	Solid Tumour	Capivasertib Midazolam	18 Years - 130 Years	AstraZeneca
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer	NCT04087174	Prostate Cancer	Capivasertib Enzalutamide Abiraterone	18 Years - 130 Years	AstraZeneca
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC	NCT03997123	Triple Negative...	Capivasertib Paclitaxel Placebo	18 Years - 130 Years	AstraZeneca
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body	NCT04712396	Healthy Volunte...	Capivasertib Itraconazole	18 Years - 58 Years	AstraZeneca
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss	NCT05593497	High-Risk Prost...	Capivasertib abiraterone ace...	18 Years -	VA Office of Research and Development
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer	NCT04556773	Metastatic Brea...	Trastuzumab der... Durvalumab Paclitaxel Capivasertib Anastrozole Fulvestrant Capecitabine	18 Years -	AstraZeneca
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)	NCT05348577	Prostate Cancer	capivasertib docetaxel placebo docetaxel	18 Years - 130 Years	AstraZeneca
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer	NCT04087174	Prostate Cancer	Capivasertib Enzalutamide Abiraterone	18 Years - 130 Years	AstraZeneca
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer	NCT03801369	Anatomic Stage ... Metastatic Trip...	Biopsy Capivasertib Ceralasertib Durvalumab Olaparib Quality-of-Life... Selumetinib	18 Years -	OHSU Knight Cancer Institute
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body	NCT04712396	Healthy Volunte...	Capivasertib Itraconazole	18 Years - 58 Years	AstraZeneca
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer	NCT05563220	Breast Cancer Metastatic Brea...	Elacestrant Alpelisib Everolimus Ribociclib Palbociclib Capivasertib Abemaciclib	18 Years -	Stemline Therapeutics, Inc.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC	NCT05720260	Premenopausal B... Metastatic Brea... ER Positive Bre...	Goserelin Fulvestrant Capivasertib Durvalumab	20 Years -	National Taiwan University Hospital
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours	NCT04958226	Solid Tumour	Capivasertib Midazolam	18 Years - 130 Years	AstraZeneca
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency	NCT04493853	Hormone-Sensiti...	Capivasertib Placebo Abiraterone Ace...	18 Years - 130 Years	AstraZeneca
PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer	NCT02423603	Metastatic Brea...	Paclitaxel AZD5363 Placebo	18 Years -	Queen Mary University of London
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: